Aclaris Therapeutics Announced Phase 1b Proof-of-Concept Primary Analysis Results For ATI-052 In Atopic Dermatitis, Asthma, Demonstrating Rapid, Durable Skin, Itch Improvement, Improved Lung Function, Airway Inflammation

Loading news article.

Aclaris Therapeutics Announced Phase 1b Proof-of-Concept Primary Analysis Results For ATI-052 In Atopic Dermatitis, Asthma, Demonstrating Rapid, Durable Skin, Itch Improvement, Improved Lung Function, Airway Inflammation | WAPE

Aclaris Therapeutics Announced Phase 1b Proof-of-Concept Primary Analysis Results For ATI-052 In Atopic Dermatitis, Asthma, Demonstrating Rapid, Durable Skin, Itch Improvement, Improved Lung Function, Airway Inflammation

Article summary

Related companies

Comments —